June 3, 2015
Astellas Pharma announced on June 2 that its oral androgen receptor inhibitor Xtandi (enzalutamide) monotherapy met the primary endpoint in a PII study in patients with advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC). The data were presented at...read more